Gal-3 blocks the binding between PD-1 and pembrolizumab

Gal-3 blocks the binding between PD-1 and pembrolizumab

Introduction Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic malignant melanoma (MM) and improved long-term survival. Despite the impressive results, some patients still have progressive disease, and the search for biomarkers predicting response to ICI treatment is...

Full description

Saved in:
Bibliographic Details
Main Authors: Henrik Schmidt, Torben Steiniche, Bent Deleuran, Malene Hvid, Morten Aagaard Nielsen, Stinne Ravn Greisen, Mia Bendix, Kathrine Pedersen, Nina Haunstrup Jensen, Jakob Hauge Mikkelsen, Taner Drace, Thomas Boesen
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/10/e009952.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/10/e009952.full

Similar Items